The Use of Regenerative Abilities of Cord Blood Stem Cells in Patients with Dilated Cardiomyopathy
Abstract
Induction. We have analyzed the results of treatment of patients with dilated cardiomyopathy (DCM) where medicinal therapy has been supplemented with cord blood stem cells transplantation (CBSCT).
The aim. Comparative analysis of DCM patients treatment effectiveness using cord blood
stem cells.
Materials and Methods. To analyze effectiveness of stem therapy after 3, 6 and 12 month after transplantation, we have analyzed 40 patients with chronic heart failure against the background of DCM. We have formed a group of patients with only medicinal therapy (n=20), and a group where, in addition to medicinal therapy, CBSCT has been used (n=20). Medicinal therapy has been done according to the common standards. CBSCT has been done by means of intravenous drip injection of cryopreserved human cord blood with cells concentration in general volume from 0.890*109 to 0.950*109.
Results and Discussion. CBSCT for patients with DCM allowed to increase left ventricle ejection fraction by 26.9% after 12 month of prospectus observation, improve the parameters of systolic and diastolic left ventricle function, longitudinal, transmural and circular deformation parameters, in contrast to the conservative therapy. The quality of life analysis proved both physical and mental health enhancement, Minnesota Questionnaire negative life quality grade score decrease by 40.3% compared to the baseline. According to our data, stem cell transplantation procedure itself has not increased the risk of dangerous ventricle arrhythmia. However, the DCM is considered as proarrhythmogenic state of the patients.
In contrast to the conservative treatment, clinical improvement of state in patients with DCM after the complex therapy which includes CBSCT is accompanied by cardiovascular survival and the decrease of cardiovascular mortality by 15%.
Conclusion. The use of cord blood stem cells in patients with DCM treatment complex is an effective and safe treatment method which allows to increase the left ventricle contraction function, improve the patient’s state and decrease heart failure signs.
References
- Qureshi WT, Zhang ZM, Chang PP, Rosamond WD, Kitzman DW, Wagenknecht LE, et al. Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study. J Am Coll Cardiol. 2018;71(1):1-8. https://doi.org/10.1016/j.jacc.2017.10.071
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; for American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4): e29-e322. https://doi.org/10.1161/CIR.0000000000000152
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur. Heart Jour. 2016;37(27):2129-2200. https://doi.org/10.1093/eurheartj/ehw128
- Alba AC, Foroutan F, Duero Posada J, Battioni L, Schofield T, Alhussein M, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. 2018;104(3):230-236. https://doi.org/10.1136/heartjnl-2017-311430
- Nanayakkara S, Patel HC, Kaye DM. Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clin Med Insights Cardiol. 2018;12: 1179546817751609. https://doi.org/10.1177/1179546817751609
- Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus heme: Allograft ischemic time. J Heart Lung Transplant. 2017 Oct;36(10):1037-1046. https://doi.org/10.1016/j.healun.2017.07.019
- Papa AA, D’Ambrosio P, Petillo R, Palladino A, Politano L. Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series. Intractable Rare Dis Res. 2017;6(2):95-101. https://doi.org/10.5582/irdr.2017.01024
- Shah S, Asante-Korang A, Ghazarian SR, Stapleton G, Herbert C, Decker J, et al. Risk Factors for Survival After Heart Transplantation in Children and Young Adults: A 22-Year Study of 179 Transplants. World J Pediatr ongenit Heart Surg. 2018;9(5):557-564. https://doi.org/10.1177/2150135118782190
- Serfas JD, Patel PA, Krasuski RA. Heart Transplantation and Mechanical Circulatory Support in Adults with Congenital Heart Disease. Curr Cardiol Rep. 2018;20(10):81. https://doi.org/10.1007/s11886-018-1028-1
- Mukdad L, Mantha A, Aguayo E, Sanaiha Y, Juo YY, Ziaeian B, et al. Readmission and resource utilization after orthotopic heart transplant versus ventricular assist device in the National Readmissions Database, 2010-2014. Surgery. 2018;164(2):274-81. https://doi.org/10.1016/j.surg.2018.04.013
- Patel N, Kalra R, Doshi R, Bajaj NS, Arora G, Arora P. Trends and Cost of Heart Transplantation and Left Ventricular Assist Devices: Impact of Proposed Federal Cuts. JACC Heart Fail. 2018;6(5):424-432.https://doi.org/10.1016/j.jchf.2018.03.005
- Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report – 2013; Focus Theme: Age. J. Heart Lung Transplant. 2013;32(10):951-964. https://doi.org/10.1016/j.healun.2013.08.006
- Blair A. The Use of Left Ventricular Assist Devices in End-Stage Heart Failure. Crit Care Nurs Q.2018;41(4):376-382. https://doi.org/10.1097/CNQ.0000000000000223
- Parameshwar J, Hogg R, Rushton S, Taylor R, Shaw S, Mehew J, et al. Patient survival and therapeutic outcome in the UK bridge to transplant left ventricular assist device population. Heart. 2019 Feb;105(4):291-296. https://doi.org/10.1136/heartjnl-2018-313355. Epub 2018 Aug 18.
- Schmidt T, Bjarnason-Wehrens B, Schulte-Eistrup S, Reiss N. Effects of pump speed changes on exercise capacity in patients supported with a left ventricular assist device-an overview. J Thorac Dis. 2018;10(Suppl 15):S1802-S1810. https://doi.org/10.21037/jtd.2018.01.114
- Gryn VK, Mikhailichenko VYu. [Pathophisiogist aspect of cells cardiomyoplastics in heart with experimental myocardial infarct]. Tavricheskiy Mediko-Biologicheskiy Vestnik. 2012;15(3 Supll 1 (59)): 81-84. Russian.
- Hollweck T, Hagl C, Eissner G. Mesenchymal stem cells from umbilical cord tissue as potential therapeutics for cardiomyodegenerative diseases – a review. Int J Mo1 Cell Med. 2012;1(3):119-132.
- Matiashchuk AS. Otsinka skorotlyvoi funktsii livoho shlunochka metodom kartuvannia deformatsii na etapakh khirurhichnoho likuvannia khvorykh na ishemichnu khvorobu sertsia [Left ventricular contractile function evaluation of the patients with coronary heart disease by strain rate imaging method in surgery treatment stages] [dissertation]. Kyiv: State Institute “Shalimov’s National Institute of Surgery and Transplantation” to National Academy of Medical Sciences of Ukraine; 2017. Ukrainian.
